Universal Biosensors executes US distribution deal
Electrochemical test developer Universal Biosensors has signed another distribution deal in the United States for the company’s Sentia wine testing platform device. Vinmetrica (USA) will be non-exclusive distributor for a three year term for Sentia, which tests wine for sulphur dioxide, glucose, malic acid and other components of wine. The agreement is for a three year term and includes initial purchase volumes of devices and test strips. Universal said that it had now achieved $1 million in sales for Sentia test devices and strips.
Custom Denning Element e-bus hits the road in Sydney
The first of six Transport for NSW compliant Custom Denning Element buses (pictured) was delivered to Busways Penrith in western Sydney yesterday. According to Custom Denning: “A huge day for the future, with Electric Buses designed and manufactured in Australia by Custom Denning.” The Element utilises many components already in use by OEM’s throughout Europe, however with novel battery and electric motor technology. Utilising solid state batteries that are designed to operate in harsher climates without the need of cooling systems, the expected running time on a full charge is approximately 16 hours or 300km, with a full recharge time of approximately 5 hours.
BlueScope looks at hydrogen for its Port Kembla steel works – report
Sleel slab and coil producer BlueScope appears to have accelerated its consideration of using hydrogen as a reductant in steel making to cut harmful emissions. The company had previously indicated it saw hydrogen as useful in the medium term once technology had advanced. However abc.net.au reported that it now planned a 10-megawatt hydrogen electrolyser. However the company would ultimately need to use 300MW of hydrogen to replace coke in the blast furnace. BlueScope’s technologies head Chris Page said: “And further if we want to go to (full hydrogen steel production) we are going to need something like 1,400MW to do that.”
Noxopharm gains Australian and European patent protection
Drug development company Noxopharm has reported it has received new approvals for patent claims relating to its anti-caner drug Veyonda in Australia and Europe. Veyonda is a formulation of the drug idronoxil, with claims for Veyonda now allowed for enabling lower, safer dosages of common chemotherapies. The Sydney company said the claim is to enable provision of active cancer therapy to a significant proportion of patients who are unable to undergo full-strength chemotherapy. The new claims were previously allowed in Japan.
Picture: Custom Denning
Subscribe to our free @AuManufacturing newsletter here.